Trial Title:
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
NCT ID:
NCT05824494
Condition:
Uterine Cervical Neoplasms
Cancer of Cervix
Cervical Cancer
Cervical Neoplasms
Uterine Cervical Cancer
Cancer of the Uterine Cervix
Conditions: Official terms:
Neoplasms
Uterine Cervical Neoplasms
Paclitaxel
Conditions: Keywords:
PD-1
immune checkpoint inhibitor
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
cadonilimab 10mg/kg Q3W and nab-paclitaxel ≤260mg/m2 Q3W
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Cadonilimab
Description:
Cadonilimab 10mg/kg,every 3 weeks,IV infusion
Arm group label:
Cadonilimab plus nab-paclitaxel
Intervention type:
Drug
Intervention name:
Nab paclitaxel
Description:
Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
Arm group label:
Cadonilimab plus nab-paclitaxel
Summary:
This is a phase II trial of combination therapy of cadonilimab(Bispecific
Anti-PD-1/CTLA-4 Antibody) plus nab-Paclitaxel in patients with recurrent or metastatic
cervical cancer that had failed PD-1/PD-L1 blockade therapy. As a bispecific antibody
against PD-1 and CTLA-4, cardonirimab can not only induce the production of a large
number of T cells in the early stage of immune response by antagonizing CTLA-4, but also
block PD-1 and PD-L1/L2 combination. Thereby restoring the killing function of T cells to
tumor cells and reducing the exhaustion of T cells.The hypothesis is the combination of
cadonilimab and nab-Paclitaxel will overcome PD-1/PD-L1 blockade-resistance to enhance
the response of patients with persistant, recurrent or metastatic cervical cancer.
Detailed description:
Primary objective:
Objective response rate for cadonilimab in combination with nab-paclitaxel in the
treatment of persistent, recurrent, or metastatic cervical cancer previously treated with
immune checkpoint inhibitors.
Secondary objective:
To evaluate duration of response (DoR) and disease control rate (DCR) of cardinirimab
combined with nab-paclitaxel in the treatment of persistent, recurrent or metastatic
cervical cancer who have previously received immune checkpoint inhibitor therapy based on
RECIST v1.1 and time to response (TTR).
To evaluate the progression-free survival (PFS) and overall survival (OS) of patients
with persistent, recurrent or metastatic cervical cancer who had previously received
immune checkpoint inhibitor therapy with cardonilimab combined with nab-paclitaxel.
To evaluate the safety and tolerability of this combination therapy.
Exploratory objective:
To search for potential indicators in tumor tissue or peripheral blood of subjects that
can predict the efficacy of cardonirimab combined with nab-paclitaxel.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Subjects are autonomous and fully autonomous, understand and voluntarily sign a
written informed consent within 30 days before enrollment.
2. Age ≥ 18 and ≤ 75 years old on the date of signing the informed consent form,
female.
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
4. Expected survival period ≥ 3 months.
5. Persistent, recurrent or metastatic cervical cancer confirmed by histology or
cytology.
6. Subjects who have previously failed treatment with PD-1, PD-L1 or CTLA4 inhibitors.
7. There is at least one measurable tumor lesion according to the RECIST v1.1 standard;
tumor lesions in the previous radiotherapy area or other locoregional treatment
sites are generally not regarded as measurable lesions, unless the lesion has
definite progression and persists after 3 months of radiotherapy, Or the tumor
nature of the lesion is confirmed by biopsy.
8. All subjects need to provide informed consent to provide freshly obtained tumor
tissue samples or tumor tissue samples archived within 5 years (formalin-fixed
paraffin-embedded [FFPE] tissue wax blocks or at least 5 unstained tumor tissue
Biopsy samples, preferably freshly obtained tumor tissue samples). If the subject
cannot provide the tumor tissue sample archived within 5 years before randomization
or the tumor tissue sample is not suitable for use, a biopsy must be performed to
collect fresh tumor tissue; if the investigator judges that there is a safety risk
in the subject's tumor tissue biopsy, the Discuss with medical monitor.
9. The subject agrees to collect tumor tissue and peripheral blood samples required
during the screening period and the research process and apply them to relevant
research.
10. The results of laboratory tests after the screening period suggest that the subject
has good organ function:
1. Hematology (no blood components and cell growth factor supportive treatment are
allowed within 2 weeks before randomization): i. The absolute value of
neutrophils ANC ≥ 1.5 × 109/L (1,500/mm3); ii. Platelet count ≥ 100 × 109/L
(100,000/mm3); iii. Hemoglobin ≥ 90 g/L.
2. Kidneys: i. Calculated creatinine clearance* (CrCl) ≥ 50 mL/min
* CrCl will be calculated using the Cockcroft-Gault formula (Cockcroft-Gault
formula) CrCl (mL/min) = {(140 - age) × body weight (kg) × 0.85}/ (serum
creatinine. (mg/dL) × 72) ii. Urinary protein < 2+ or 24-hour (h) urine protein
quantitative < 1.0 g.
3. Liver: i. Serum total bilirubin (TBil) ≤ 1.5 × ULN ii. AST and ALT ≤ 2.5× ULN
iii. Serum albumin (ALB) ≥ 28 g/L
4. coagulation function: i. International normalized ratio (INR) and activated
partial thromboplastin time (APTT) ≤ 1.5 × ULN (if the subject is receiving
anticoagulant therapy, the subject must receive a stable dose of anticoagulant
and coagulation parameters at the time of screening (PT/INR and APTT) were
within expected ranges with anticoagulant therapy).
5. Cardiac function: i. Left ventricular ejection fraction (LVEF) ≥ 50%.
11. Female subjects of childbearing potential must have a serum pregnancy test within 3
days before the first dose and the result is negative. If a female subject of
childbearing potential has sex with an unsterilized male partner, the subject must
use an acceptable and effective method of contraception since screening and must
agree to continue using these precautions until after the last dose of the study
drug 6 months; Periodic abstinence and rhythm contraception are unacceptable
contraceptive methods.
1. Females of childbearing potential are defined as females who have not been
surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy,
or total hysterectomy) or who have not undergone menopause (menopause is
defined as at least Menopause for 12 consecutive months, serum
follicle-stimulating hormone level is within the laboratory reference range for
postmenopausal women);
2. A highly effective contraceptive method is one that has a low rate of
contraceptive failure (eg, less than 1% per year) when used correctly and
consistently. Not all birth control methods are equally effective. Female
subjects of childbearing potential must use barrier contraception or hormonal
contraception (such as oral contraceptives) to ensure that pregnancy does not
occur.
12. The subjects are willing and able to comply with the schedule of visits, treatment
plans, laboratory tests, and other requirements of the study.
Exclusion Criteria:
1. Suffering from other active malignant tumors within 3 years before randomization,
except locally curable tumor types and those who have been cured, such as Squamous
cell carcinoma of the skin, basal cell carcinoma of the skin, superficial bladder
cancer, carcinoma in situ of the breast.
2. Severe immunotherapy-related toxicity occurred during the previous anti-PD-1/PD-L1
monoclonal antibody treatment, including but not limited to: grade 3/4 pneumonia,
proteinuria, uveitis or episcleritis, myasthenia gravis, Pancreatitis, hepatitis,
bullous skin disease (including SJS, TEN); grade 2-4 encephalitis, myocarditis; any
grade of Guillain-Barré syndrome, transverse myelitis; severe inflammation that
significantly affects the quality of life of the patient sex joints.
3. Received chemotherapy, radiotherapy, biological therapy, endocrine therapy,
immunotherapy, or other unmarketed clinical research drugs and other anti-tumor
treatments within 4 weeks before the first use of the study drug.
4. Received nab-paclitaxel drug therapy within 6 months before the first use of the
study drug. Known contraindications to nab-paclitaxel or hypersensitivity to any of
its components.
5. Received drugs with immunomodulatory effects (such as thymosin, interferon,
interleukin-2) within 2 weeks before randomization; received Chinese patent
medicines with anti-tumor indications (such as Aidi injection, etc.) within 2 weeks
before randomization.
6. Received major organ surgery (not including needle biopsy, etc.) or experienced
significant trauma within 4 weeks before the first use of the study drug, or
required elective surgery during the trial
7. There is central nervous system metastasis or cancerous meningitis.
8. Pleural effusion, pericardial effusion, or peritoneal effusion with uncontrollable
need for repeated drainage (more than once a month) of subjects.
9. Suffering from active or recurrent autoimmune diseases; except the following:
vitiligo, alopecia, psoriasis, or eczema that do not require systemic treatment;
hypothyroidism caused by autoimmune thyroiditis that only requires stable doses of
Hormone replacement therapy; type 1 diabetes requiring only a steady dose of insulin
replacement therapy.
10. Subjects who need to use > 10 mg/day prednisone or equivalent dose of glucocorticoid
or other immunosuppressive drugs for systemic treatment within 14 days before
randomization; except the following
1. Inhaled, ophthalmic or topical glucocorticoid therapy with a dose of ≤ 10
mg/day prednisone or equivalent dose is allowed.
2. Physiological glucocorticoid replacement therapy, with a dose of ≤ 10 mg/day
prednisone or an equivalent dose of glucocorticoid.
3. Glucocorticoids as prophylaxis for hypersensitivity reactions (eg, before CT
examination).
11. Live vaccines have been used within 4 weeks before randomization.
12. Known primary or secondary immunodeficiency, including human immunodeficiency virus
(HIV) antibody test positive.
13. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem
cell transplantation.
14. Known history of interstitial lung disease or non-infectious pneumonia.
15. Serious infection occurred within 4 weeks before randomization, including but not
limited to complications requiring hospitalization, sepsis or severe pneumonia.
16. There are active infections that require systemic treatment (including active
tuberculosis and active Treponema pallidum infection), and have used systemic
antibacterial, antiviral or antifungal drugs within 2 weeks before randomization;
Note: for type B Antiviral drugs used for viral hepatitis are excluded.
17. Active hepatitis B subjects, inactive or asymptomatic hepatitis B virus (HBV)
carriers (hepatitis B surface antigen [HBsAg] positive) and HBV DNA> 1000 IU/mL),
and subjects with active hepatitis C virus.
18. Suffering from active or documented inflammatory bowel disease (such as Crohn's
disease, ulcerative colitis), active diverticulitis. There are clinical
manifestations of gastrointestinal obstruction, or routine parenteral fluid
rehydration, parenteral nutrition, or indwelling gastric tube are required.
19. Any of the following cardiovascular and cerebrovascular diseases:
1. Myocardial infarction, unstable angina, pulmonary embolism, aortic dissection,
deep venous thrombosis and any arterial thromboembolic events occurred within 6
months before randomization;
2. Heart failure with New York Heart Association (NYHA) functional class ≥ II;
3. There are severe arrhythmias that require long-term drug intervention; patients
with atrial fibrillation who are asymptomatic and have stable ventricular rates
are allowed;
4. Cerebrovascular events (CVA) occurred within 6 months before randomization;
5. Left ventricular ejection fraction (LVEF) < 50%;
6. Previous history of myocarditis or cardiomyopathy.
7. Hypertension (defined as systolic blood pressure > 150 mmHg, diastolic blood
pressure > 100 mmHg) that remains uncontrolled after adequate antihypertensive
drug treatment, or a history of hypertensive crisis or hypertensive
encephalopathy.
20) Known history of severe hypersensitivity to other monoclonal antibodies.
21) NCI CTCAE v5.0 ≥ grade 3 peripheral neuropathy exists. 22) The
toxicity of previous anti-tumor therapy has not been relieved, defined as
the toxicity has not recovered to NCI CTCAE v5.0 ≤ 2 grades, or the level
specified in the inclusion/exclusion criteria (except hair loss) 23) The
investigator believes that it may lead to risk of receiving the study drug
treatment, or any condition that will interfere with the evaluation of the
study drug or the safety of the subjects or the interpretation of the
study results (such as suffering from other serious diseases or mental
diseases, etc.).
24) Enroll in another clinical study at the same time, unless it is an
observational, non-interventional clinical study or follow-up period of an
interventional study.
25) Pregnant or lactating women. 26) Subjects considered by the investigator
to be inappropriate to participate in the trial due to other reasons.
Gender:
Female
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Start date:
June 2023
Completion date:
June 2026
Lead sponsor:
Agency:
Women's Hospital School Of Medicine Zhejiang University
Agency class:
Other
Collaborator:
Agency:
Akeso
Agency class:
Industry
Source:
Women's Hospital School Of Medicine Zhejiang University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05824494
